Revising the ABIDE MCI to dementia prediction model for automated cerebrospinal fluid assays

Automated cerebrospinal fluid (CSF) biomarker assays have largely replaced manual immunoassays for measuring amyloid pathology in CSF. We refitted and validated the ABIDE model, predicting progression from mild cognitive impairment (MCI) to dementia, with CSF measurements from the automated Elecsys...

Descripción completa

Detalles Bibliográficos
Autores: van der Veere, Pieter, van Harten, Argonde, van Maurik, Ingrid, Teunissen, Charlotte, Barkhof, Frederik, Vos, Stephanie, Froelich, Lutz, Kornhuber, Johannes, Wiltfang, Jens, Maier, Wolfgang, Peters, Oliver, Rüther, Eckart, Frisoni, Giovanni, Spiru, Luiza, Freund-Levi, Yvonne, Wallin, Åsa K, Hampel, Harald, Tsolaki, Magda, Kłoszewska, Iwona, Mecocci, Patrizia, Vellas, Bruno, Lovestone, Simon, Galluzzi, Samantha, Herukka, Sanna-Kaisa, Santana, Isabel, Baldeiras, I., de Mendonca, Alexandre, Silva, Dina, Chetelat, Gael, Poisnel, Géraldine, Visser, Pieter Jelle, Johnson, Sterling, Stormrud, Erik, Hansson, Oskar, Palmqvist, Sebastian, Piñol Ripoll, Gerard, Berkhof, Johannes, van der Flier, Wiesje
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2026
País:España
Institución:Universitat de Lleida (UdL)
Repositorio:Repositori Obert UdL
OAI Identifier:oai:repositori.udl.cat:10459.1/469733
Acceso en línea:https://doi.org/10.1002/alz.71192
https://hdl.handle.net/10459.1/469733
Access Level:acceso abierto
Palabra clave:Alzheimer's disease
Automated cerebrospinal fluid assays
Cerebrospinal fluid
Dementia
Mild cognitive dementia
Prediction
Descripción
Sumario:Automated cerebrospinal fluid (CSF) biomarker assays have largely replaced manual immunoassays for measuring amyloid pathology in CSF. We refitted and validated the ABIDE model, predicting progression from mild cognitive impairment (MCI) to dementia, with CSF measurements from the automated Elecsys platform. We included 2413 MCI participants (998 [41%] amyloid-positive) from seven observational cohorts. Elecsys was used in 958 (40%) participants. The parameters of the previous ABIDE Cox model were re-estimated. Model discrimination and calibration were evaluated with leave-one-cohort-out cross-validation. During follow-up, 1034 (42%; 585 [58%] amyloid-positive) participants developed dementia. Discrimination was good with Harrell's C of 0.70 (95% confidence interval [CI]: 0.66-0.73). Calibration was good in the total population and amyloid-positive subgroup, with substantial predicted progression risks for all amyloid-positive participants. We refitted the ABIDE model, predicting MCI to dementia progression, with automated CSF measurements. The model was well calibrated in amyloid-positive patients and may support clinical discussions regarding ATTs.

Similares en LA Referencia